Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov;136(5):1399-1401.e3.
doi: 10.1016/j.jaci.2015.07.034. Epub 2015 Sep 18.

Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment

Ruby F Fernandez-Boyanapalli  1 , Emilia Liana Falcone  2 , Christa S Zerbe  2 , Beatriz E Marciano  2 , S Courtney Frasch  1 , Peter M Henson  1 , Steven M Holland #  2 , Donna L Bratton #  1
Affiliations

Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment

Ruby F Fernandez-Boyanapalli et al. J Allergy Clin Immunol. 2015 Nov.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Impaired efferocytosis by CGD monocytes is restored by pioglitazone treatment ex vivo. A. Freshly isolated monocytes from CGD and normal subjects were “fed” fluorescently labeled apoptotic Jurkat cells (left) or carboxylated beads (right) N=9 subjects/group. B. Overnight-shipped CGD and normal monocytes, plated and treated for 24h with pioglitazone or vehicle, were then “fed” carboxylated beads as in A. N=5 subjects/group.
Fig. 2
Fig. 2
Efferocytosis is restored and mitochondrial oxidant production enhanced in monocytes isolated from CGD patients during treatment with pioglitazone. A. Efferocytosis by CGD monocytes appears to be restored (compared to normal monocytes) following pioglitazone treatment of at least 30 days in 2 CGD subjects. Patient data are shown as mean ± range for duplicate wells at each time point. B. Mitochondrial oxidant production by stimulated CGD monocytes was enhanced during treatment with pioglitazone.
See this image and copyright information in PMC

References

    1. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol. 2010;38:3–10. - PubMed
    1. Fernandez-Boyanapalli R, Frasch SC, Riches DW, Vandivier RW, Henson PM, Bratton DL. PPARgamma activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood. 2010;116:4512–22. - PMC - PubMed
    1. Zeng MY, Pham D, Bagaitkar J, Liu J, Otero K, Shan M, et al. An efferocytosis-induced, IL-4-dependent macrophage-iNKT cell circuit suppresses sterile inflammation and is defective in murine CGD. Blood. 2013;121:3473–83. - PMC - PubMed
    1. Sanmun D, Witasp E, Jitkaew S, Tyurina YY, Kagan VE, Ahlin A, et al. Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease. Am J Physiol Cell Physiol. 2009;297:C621–31. - PubMed
    1. Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol. 2003;73:591–9. - PubMed

Publication types

MeSH terms